छोड़कर सामग्री पर जाएँ

Latest News

Buy Krishna Institute of Medical Sciences; target of Rs 2000: Prabhudas Lilladher

Buy Krishna Institute of Medical Sciences; target of Rs 2000: Prabhudas Lilladher

Prabhudas Lilladher is bullish on Krishna Institute of Medical Sciences has recommended buy rating on the stock with a target price of Rs 2000 in its research report dated August 09, 2023. Read More ​ Prabhudas Lilladher is bullish on Krishna… और पढ़ें »Buy Krishna Institute of Medical Sciences; target of Rs 2000: Prabhudas Lilladher

Buy J.B. Chemicals and Pharmaceuticals Institute; target of Rs 3000: Prabhudas Lilladher

Buy J.B. Chemicals and Pharmaceuticals Institute; target of Rs 3000: Prabhudas Lilladher

Prabhudas Lilladher is bullish on J.B. Chemicals and Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 3000 in its research report dated August 10, 2023. Read More ​ Prabhudas Lilladher is bullish on J.B. Chemicals… और पढ़ें »Buy J.B. Chemicals and Pharmaceuticals Institute; target of Rs 3000: Prabhudas Lilladher

Independence Day box office will touch Rs 100 crore from films like Jailer, Gadar 2, says analyst

Independence Day box office will touch Rs 100 crore from films like Jailer, Gadar 2, says analyst

Lucrative periods like the August 15 holiday will help the India box office make up for the shortfall in the first half of 2023, said an analyst. Read More ​ Lucrative periods like the August 15 holiday will help the India… और पढ़ें »Independence Day box office will touch Rs 100 crore from films like Jailer, Gadar 2, says analyst

Abans Holdings gets board#39;s nod to enter mutual funds space

Abans Holdings gets board#39;s nod to enter mutual funds space

This subsidiary will focus on lending business operations, strengthening the company’s foothold in the lending segment. Abans Holdings is looking to become a dominant player in alternative investments. Read More ​ This subsidiary will focus on lending business operations, strengthening the… और पढ़ें »Abans Holdings gets board#39;s nod to enter mutual funds space

Biocon may list biosimilars business by 2025 first half – CEO

Biocon may list biosimilars business by 2025 first half – CEO

Biocon Biologics, a fully integrated subsidiary of Biocon Ltd, focuses on making biosimilars, with key revenue-generating markets being the United States and Europe. Read More ​ Biocon Biologics, a fully integrated subsidiary of Biocon Ltd, focuses on making biosimilars, with key… और पढ़ें »Biocon may list biosimilars business by 2025 first half – CEO

Biocon may list biosimilars business by 2025 first half – CEO

Biocon may list biosimilars business by 2025 first half – CEO

Biocon Biologics, a fully integrated subsidiary of Biocon Ltd, focuses on making biosimilars, with key revenue-generating markets being the United States and Europe. Read More ​ Biocon Biologics, a fully integrated subsidiary of Biocon Ltd, focuses on making biosimilars, with key… और पढ़ें »Biocon may list biosimilars business by 2025 first half – CEO

hi_INहिन्दी